An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

Trial Profile

An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms BARRIER-P
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
    • 24 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018.
    • 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top